Zosano Pharma Corporation (ZSAN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zosano Pharma Corporation (ZSAN) with AI Score 61/100 (Grade B+). Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on migraine treatment using a transdermal microneedle system. The company filed for Chapter 11 reorganization in June 2022. Sector: Healthcare.
Last analyzed: Mar 18, 2026ZSAN: the 3 perspectives are evenly split. Dominant signal: Izzy Englander bearish.
Zosano Pharma Corporation (ZSAN) Healthcare & Pipeline Overview
Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, develops therapeutics for migraine using its microneedle delivery system, Qtrypta. Currently undergoing Chapter 11 reorganization, Zosano faces significant financial and operational hurdles in a competitive biotechnology landscape dominated by larger pharmaceutical firms.
What Is the Investment Thesis for ZSAN?
Investing in Zosano Pharma Corporation presents a highly speculative opportunity due to its Chapter 11 reorganization. The company's future hinges on its ability to restructure its debt, secure additional funding, and successfully commercialize Qtrypta. While the microneedle delivery system offers a potentially differentiated approach to migraine treatment, the company faces significant financial and operational hurdles. Key metrics to monitor include the progress of the bankruptcy proceedings, any potential partnerships or acquisitions, and the regulatory pathway for Qtrypta. The company's negative profit margin of -3836.2% and gross margin of -1.4% highlight the severity of its financial situation. The high beta of 3.29 indicates significant volatility.
Based on FMP financials and quantitative analysis
ZSAN Key Highlights
- Qtrypta (M207) is Zosano's lead product candidate, a proprietary formulation of zolmitriptan for acute migraine treatment.
- The company filed for Chapter 11 reorganization on June 1, 2022, indicating significant financial distress.
- Zosano's transdermal microneedle system offers a potentially faster and more convenient alternative to oral migraine medications.
- The company's negative profit margin of -3836.2% reflects substantial losses.
- Zosano has a high beta of 3.29, indicating significant stock price volatility.
Who Are ZSAN's Competitors?
Who Are ZSAN's Competitors?
ZSAN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| KRON Kronos Bio, Inc. | $0.88 | +1.49% | $53.65M | 65 |
| LABP Landos Biopharma, Inc. | $22.93 | +0.00% | $71.68M | — |
| SNDX Syndax Pharmaceuticals, Inc. | $17.34 | -3.77% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $57.69 | +1.54% | $2.49B | 79 |
| ABVX Abivax S.A. | $124.65 | -1.49% | 9B | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.31 | +0.00% | $406.52M | 76 |
| ZYME Zymeworks Inc. | $25.48 | +2.78% | 2B | 68 |
| BCYC Bicycle Therapeutics plc | $4.45 | -4.71% | 309M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZSAN's Key Strengths?
- Innovative transdermal microneedle technology.
- Potential for faster drug absorption and improved patient compliance.
- Lead product candidate (Qtrypta) targets a large market.
- Experienced management team (prior to Chapter 11).
What Are ZSAN's Weaknesses?
- Chapter 11 reorganization indicates severe financial distress.
- Negative profit and gross margins.
- Dependence on a single product candidate.
- Limited resources for commercialization.
What Could Drive ZSAN Stock Higher?
- Chapter 11 reorganization proceedings and potential restructuring plans.
- Potential for securing additional funding or strategic partnerships.
- Regulatory updates regarding Qtrypta's approval pathway.
What Are the Key Risks for ZSAN?
- Financial instability and the risk of liquidation.
- Failure to secure additional funding or restructure debt.
- Regulatory delays or rejection of Qtrypta.
- Competition from established migraine treatments.
- Uncertainty surrounding the company's future direction.
What Are the Growth Opportunities for ZSAN?
- Expansion of Qtrypta into new markets: Zosano could pursue regulatory approval and commercialization of Qtrypta in international markets, such as Europe and Asia, to expand its revenue base. The global migraine market is estimated to reach billions of dollars, offering significant potential for growth. However, this is contingent on the company successfully navigating its Chapter 11 reorganization and securing the necessary funding and partnerships.
- Development of new formulations using the microneedle technology: Zosano could leverage its transdermal microneedle system to develop new formulations of existing migraine medications or explore its application for delivering other types of drugs. This could create new revenue streams and diversify the company's product portfolio. The timeline for this growth opportunity is uncertain, given the company's current financial constraints.
- Strategic partnerships with pharmaceutical companies: Zosano could seek partnerships with larger pharmaceutical companies to co-develop and commercialize Qtrypta or other pipeline assets. This could provide access to additional funding, expertise, and distribution channels. The success of this strategy depends on Zosano's ability to attract potential partners, which may be challenging given its current financial situation.
- Acquisition by a larger pharmaceutical company: Zosano's innovative microneedle technology and Qtrypta could make it an attractive acquisition target for a larger pharmaceutical company seeking to expand its migraine treatment portfolio. An acquisition could provide Zosano's shareholders with a return on their investment. However, the likelihood of an acquisition is uncertain and depends on various factors, including the company's financial performance and the interest of potential acquirers.
- Securing additional funding to continue operations: Zosano's most immediate growth opportunity lies in securing additional funding to emerge from Chapter 11 and continue its operations. This could involve raising capital through debt or equity financing, or restructuring its existing debt obligations. The company's ability to secure funding will be critical to its long-term survival and growth prospects. The timeline for this opportunity is immediate and essential for the company's future.
What Opportunities Does ZSAN Have?
- Expansion into new markets.
- Development of new formulations using the microneedle technology.
- Strategic partnerships with pharmaceutical companies.
- Acquisition by a larger pharmaceutical company.
What Threats Does ZSAN Face?
- Competition from established migraine treatments.
- Regulatory hurdles and clinical trial risks.
- Inability to secure additional funding.
- Product liability risks.
What Are ZSAN's Competitive Advantages?
- Proprietary transdermal microneedle technology.
- Patents protecting its drug formulations and delivery systems.
- Potential for faster drug absorption and improved patient compliance.
- First-mover advantage in the microneedle migraine treatment market.
What Does ZSAN Do?
Founded in 2006 and headquartered in Fremont, California, Zosano Pharma Corporation is a clinical-stage biopharmaceutical company dedicated to developing and commercializing products for migraine treatment. The company's core technology revolves around a transdermal microneedle system designed to deliver therapeutics and other bioactive molecules directly through the skin, offering a potentially faster and more convenient alternative to traditional oral medications. Zosano's lead product candidate, Qtrypta (M207), is a proprietary formulation of zolmitriptan intended for the acute treatment of migraine. This innovative delivery method aims to improve drug absorption and reduce the onset time for migraine relief. However, on June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, indicating substantial financial challenges. The company's future hinges on its ability to navigate these challenges and potentially secure new funding or strategic partnerships to continue the development and commercialization of Qtrypta and its other pipeline assets.
What Products and Services Does ZSAN Offer?
- Develops transdermal microneedle drug delivery systems.
- Focuses on treating migraine with innovative drug delivery.
- Formulates zolmitriptan for acute migraine treatment (Qtrypta).
- Aims to provide faster and more convenient migraine relief.
- Seeks to improve drug absorption through the skin.
- Currently undergoing Chapter 11 reorganization.
How Does ZSAN Make Money?
- Develops and patents drug delivery technology.
- Seeks regulatory approval for its drug products.
- Aims to commercialize its products through partnerships or direct sales.
- Generates revenue through product sales and licensing agreements.
What Industry Does ZSAN Operate In?
Zosano Pharma Corporation operates within the competitive biotechnology industry, specifically targeting the migraine treatment market. This market is characterized by a mix of established pharmaceutical companies and innovative biotech firms developing novel therapies. The migraine therapeutics market is expected to grow, driven by an increasing prevalence of migraine disorders and the demand for more effective and convenient treatments. Zosano's microneedle delivery system represents a differentiated approach, but the company faces competition from established oral medications and emerging therapies. Competitors include companies like ACHL, HTBX, IGMS, KRON, and LABP, which are developing alternative migraine treatments.
Who Are ZSAN's Key Customers?
- Migraine sufferers seeking faster relief.
- Patients who prefer non-oral drug delivery methods.
- Healthcare providers prescribing migraine treatments.
- Pharmaceutical companies interested in licensing or acquiring new technologies.
ZSAN Financials
ZSAN Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Mar 16, 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· Oct 2, 2019
-
Stocks That Hit 52-Week Lows On Monday
· Sep 30, 2019
ZSAN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZSAN.
Price Targets
Wall Street price target analysis for ZSAN.
ZSAN MoonshotScore
What does this score mean?
The MoonshotScore rates ZSAN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are ZSAN's Competitors?
Leadership: Steven Lo
CEO
Steven Lo serves as the CEO of Zosano Pharma Corporation, managing a team of 40 employees. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on commercialization and strategic development. Prior to joining Zosano, he held leadership positions at various healthcare companies, overseeing product launches and market expansion initiatives. His expertise spans across drug development, regulatory affairs, and business development.
Track Record: Under Steven Lo's leadership, Zosano focused on advancing Qtrypta through clinical development and preparing for potential commercialization. However, the company ultimately filed for Chapter 11 reorganization, indicating significant challenges in securing funding and achieving profitability. His tenure has been marked by efforts to navigate the complex regulatory landscape and secure strategic partnerships, but the company's financial difficulties have overshadowed these efforts.
Common Questions About ZSAN (Healthcare)
What does Zosano Pharma Corporation do?
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for migraine using its proprietary transdermal microneedle system. Its lead product candidate, Qtrypta (M207), is a formulation of zolmitriptan designed for acute migraine treatment. The company aims to provide a faster and more convenient alternative to traditional oral medications. However, Zosano filed for Chapter 11 reorganization in June 2022, indicating significant financial challenges.
What do analysts say about ZSAN stock?
Given Zosano Pharma Corporation's Chapter 11 reorganization, analyst coverage is likely limited. Key valuation metrics such as P/E ratio (-2.08) and profit margin (-3836.2%) reflect the company's financial difficulties. The high beta of 3.29 indicates significant stock price volatility. Any investment in ZSAN is highly speculative and contingent on the company's ability to restructure its debt, secure additional funding, and successfully commercialize Qtrypta.
What are the main risks for ZSAN?
The primary risks for Zosano Pharma Corporation revolve around its financial instability and Chapter 11 reorganization. The company faces the risk of liquidation if it cannot secure additional funding or restructure its debt. Regulatory delays or rejection of Qtrypta also pose a significant risk. Furthermore, Zosano faces competition from established migraine treatments and the uncertainty surrounding its future direction. These risks make investing in ZSAN highly speculative.
What are the key factors to evaluate for ZSAN?
Zosano Pharma Corporation (ZSAN) currently holds an AI score of 61/100, indicating moderate score. Key strength: Innovative transdermal microneedle technology. Primary risk to monitor: Financial instability and the risk of liquidation. This is not financial advice.
How frequently does ZSAN data refresh on this page?
ZSAN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ZSAN's recent stock price performance?
Recent price movement in Zosano Pharma Corporation (ZSAN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative transdermal microneedle technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ZSAN overvalued or undervalued right now?
Determining whether Zosano Pharma Corporation (ZSAN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ZSAN?
Before investing in Zosano Pharma Corporation (ZSAN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-18. The company's financial situation is subject to change due to the Chapter 11 reorganization proceedings.